Institute of Cancer Research test repository

Repository Validation Report

Base URL:  http://repository-test.icr.ac.uk/oai/rioxx
Sample date:  2017-10-05
Sample size:  3 records harvested

Results

RecordValidation ReportsToggle Raw XML
ID: oai:repository-test.icr.ac.uk:internal/334
Date: 2016-11-24

RIOXX

Base RIOXX scheme designed for low-level interoperability
This is a valid RIOXX record

RCUK-RIOXX

RCUK RIOXX scheme for reporting of open access publications funded through UK Research Council grants
This is not a valid RCUK-RIOXX record
PropertyError
rioxxterms:type'Article' is not a valid term from the RIOXX Item-type vocabulary in rioxxterms:type
<record>
  <header>
    <identifier>oai:repository-test.icr.ac.uk:internal/334</identifier>
    <datestamp>2016-11-24T16:25:17Z</datestamp>
    <setSpec>com_123456789_179</setSpec>
    <setSpec>col_123456789_2</setSpec>
  </header>
  <metadata><rioxx:rioxx xmlns:rioxx="http://www.rioxx.net/schema/v2.0/rioxx/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:ali="http://ali.niso.org/2014/ali/1.0" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rioxxterms="http://www.rioxx.net/schema/v2.0/rioxxterms/">
<ali:free_to_read/>
<ali:license_ref start_date="2015-04-20">http://www.atmire.com/test-license</ali:license_ref>
<dc:description>Abstract</dc:description>
<dc:format>application/pdf</dc:format>
<dc:identifier>https://repository-test.icr.ac.uk/bitstream/internal/334/1/test.pdf</dc:identifier>
<dc:language>eng</dc:language>
<dc:publisher>Publisher</dc:publisher>
<dc:source>issn</dc:source>
<dc:subject>keywords</dc:subject>
<dc:title>Manual license test</dc:title>
<dcterms:dateAccepted>2015-02-20</dcterms:dateAccepted>
<rioxxterms:author first-named-author="true">test, test</rioxxterms:author>
<rioxxterms:publication_date>2015-01-20</rioxxterms:publication_date>
<rioxxterms:type>Article</rioxxterms:type>
<rioxxterms:version>AO</rioxxterms:version>
<rioxxterms:version_of_record>http://dx.doi.org/doi</rioxxterms:version_of_record>
<rioxxterms:project rioxxterms:funder_name="Default funder" rioxxterms:funder_id="http://dx.doi.org/null">Default project</rioxxterms:project>
</rioxx:rioxx>
</metadata>
</record>
ID: oai:repository-test.icr.ac.uk:123456789/17
Date: 2016-03-23

RIOXX

Base RIOXX scheme designed for low-level interoperability
This is not a valid RIOXX record
PropertyError
dcterms:dateAccepted'2004' is not in valid ISO8601 ('yyyy-mm-dd') format in dcterms:dateAccepted
ali:license_ref'2004' in the 'start_date' attribute is not in valid ISO8601 ('yyyy-mm-dd') format in ali:license_ref

RCUK-RIOXX

RCUK RIOXX scheme for reporting of open access publications funded through UK Research Council grants
This is not a valid RCUK-RIOXX record
PropertyError
rioxxterms:type'Article' is not a valid term from the RIOXX Item-type vocabulary in rioxxterms:type
dcterms:dateAccepted'2004' is not in valid ISO8601 ('yyyy-mm-dd') format in dcterms:dateAccepted
ali:license_ref'2004' in the 'start_date' attribute is not in valid ISO8601 ('yyyy-mm-dd') format in ali:license_ref
<record>
  <header>
    <identifier>oai:repository-test.icr.ac.uk:123456789/17</identifier>
    <datestamp>2016-03-23T09:29:33Z</datestamp>
    <setSpec>com_123456789_179</setSpec>
    <setSpec>col_123456789_3</setSpec>
  </header>
  <metadata><rioxx:rioxx xmlns:rioxx="http://www.rioxx.net/schema/v2.0/rioxx/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:ali="http://ali.niso.org/2014/ali/1.0" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rioxxterms="http://www.rioxx.net/schema/v2.0/rioxxterms/">
<ali:free_to_read/>
<ali:license_ref start_date="2004">http://www.rioxx.net/licenses/all-rights-reserved</ali:license_ref>
<dc:description>Intensity-modulated radiotherapy improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx Background and purpose: An investigation has been carried out into the potential of intensity-modulated radiotherapy (IMRT) to improve the coverage of the targets and the sparing of the spinal cord (SC) in radiotherapy treatment of the larynx and bilateral cervical lymph nodes, in patients with advanced larynx cancer. Patients and methods: Conventional radiotherapy (CRT) and IMRT plans were produced for six patients to treat the larynx (PTV1) and lymph nodes (PTV2) to 50 Gy (phase 1). A second plan was created to treat the PTV1 to 65 Gy and PTV2 to 50 Gy (phases I and 2). The potential to escalate the dose to both the larynx (to 67 Gy) and the nodes (to 56 Gy) was investigated for the IMRT plans. Results: The phase I treatment gave average minimum doses (dose received by 99% volume) of 38.1 (+/-8.2) and 48.5 (+/-0.2) Gy for PTV1, treated by CRT and IMRT, respectively, and 35.9 (+/-2.9) and 46.2 (+/-1.8) Gy for PTV2. For the two phase treatment the average minimum doses to PTV1 were 51.6 (+/-8.2) (CRT) and 62.1 (+/-0.7) Gy (IMRT) (P = 0.028) and for PTV2 were 36.2 (+/-2.9) (CRT) and 46.8 (+/-0.5) Gy (IMRT) (P = 0.0004). The average maximum doses (dose received by 1% volume) to the SC were 42.5 (+/-1.9) (CRT) and 37.9 (+/-1.4) Gy (IMRT) (P = 0.01). For the dose escalated IMRT plans the minimum dose to PTV1 was 64.6 (+/-0.5) and 50.8 (+/- 1.8) Gy to PTV2. The average SC maximum was 41.5 (+/-1.6) Gy. Conclusions: IMRT offers improved target homogeneity and reduces irradiation of the SC. This sparing of normal tissue structures is sufficient that significant dose escalation of both the larynx and lymph nodes may be possible. (C) 2003 Elsevier Ireland Ltd. All rights reserved.</dc:description>
<dc:format>application/pdf</dc:format>
<dc:identifier>https://repository-test.icr.ac.uk/bitstream/123456789/17/1/test.pdf</dc:identifier>
<dc:language>en</dc:language>
<dc:publisher>Elsevier</dc:publisher>
<dc:source>0167-8140</dc:source>
<dc:subject>larynx carcinoma</dc:subject>
<dc:subject>intensity-modulated radiotherapy</dc:subject>
<dc:subject>dose escalation Conformal radiotherapy</dc:subject>
<dc:title>Intensity-modulated radiotherapy improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx</dc:title>
<dcterms:dateAccepted>2004</dcterms:dateAccepted>
<rioxxterms:author first-named-author="true">Clark, C.</rioxxterms:author>
<rioxxterms:author first-named-author="false">Bidmead, A.</rioxxterms:author>
<rioxxterms:author first-named-author="false">Mubata, C.</rioxxterms:author>
<rioxxterms:author first-named-author="false">Harrington, K.</rioxxterms:author>
<rioxxterms:author first-named-author="false">Nutting, C. M.</rioxxterms:author>
<rioxxterms:publication_date>2004</rioxxterms:publication_date>
<rioxxterms:type>Article</rioxxterms:type>
<rioxxterms:version>VoR</rioxxterms:version>
<rioxxterms:project rioxxterms:funder_name="Region Hovedstaden" rioxxterms:funder_id="http://dx.doi.org/null">testproject</rioxxterms:project>
</rioxx:rioxx>
</metadata>
</record>
ID: oai:repository-test.icr.ac.uk:123456789/12
Date: 2016-03-23

RIOXX

Base RIOXX scheme designed for low-level interoperability
This is a valid RIOXX record

RCUK-RIOXX

RCUK RIOXX scheme for reporting of open access publications funded through UK Research Council grants
This is not a valid RCUK-RIOXX record
PropertyError
rioxxterms:type'Article' is not a valid term from the RIOXX Item-type vocabulary in rioxxterms:type
<record>
  <header>
    <identifier>oai:repository-test.icr.ac.uk:123456789/12</identifier>
    <datestamp>2016-03-23T09:29:10Z</datestamp>
    <setSpec>com_123456789_179</setSpec>
    <setSpec>col_123456789_4</setSpec>
  </header>
  <metadata><rioxx:rioxx xmlns:rioxx="http://www.rioxx.net/schema/v2.0/rioxx/" xmlns:doc="http://www.lyncode.com/xoai" xmlns:ali="http://ali.niso.org/2014/ali/1.0" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rioxxterms="http://www.rioxx.net/schema/v2.0/rioxxterms/">
<ali:free_to_read/>
<ali:license_ref start_date="2016-01-01">http://www.rioxx.net/licenses/all-rights-reserved</ali:license_ref>
<dc:description>Breast cancer is the commonest form of cancer in women, but successful treatment is confounded by the heterogeneous nature of breast tumours: Effective treatments exist for hormone-sensitive tumours, but triple-negative breast cancer results in poor survival. An area of increasing interest is metabolic reprogramming, whereby drug-induced alterations in the metabolic landscape of a tumour slow tumour growth and/or increase sensitivity to existing therapeutics. Nuclear receptors are transcription factors central to the expression of metabolic and transport proteins, and thus represent potential targets for metabolic reprogramming. We show that activation of the nuclear receptor FXR, either by its endogenous ligand CDCA or the synthetic GW4064, leads to cell death in four breast cancer cell lines with distinct phenotypes: MCF-10A (normal), MCF-7 (receptor positive), MDA-MB-231 and MDA-MB-468 (triple negative). Furthermore, we show that the mechanism of cell death is predominantly through the intrinsic apoptotic pathway. Finally, we demonstrate that FXR agonists do not stimulate migration in breast cancer cell lines, an important potential adverse effect. Together, our data support the continued examination of FXR agonists as a novel class of therapeutics for the treatment of breast cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.</dc:description>
<dc:format>application/pdf</dc:format>
<dc:identifier>https://repository-test.icr.ac.uk/bitstream/123456789/12/7/test.pdf</dc:identifier>
<dc:language>en</dc:language>
<dc:publisher>Elsevier</dc:publisher>
<dc:source>0304-3835</dc:source>
<dc:subject>Apoptosis</dc:subject>
<dc:subject>Autophagy</dc:subject>
<dc:subject>Nuclear receptor</dc:subject>
<dc:subject>Triple negative breast cancer</dc:subject>
<dc:subject>Bile acids</dc:subject>
<dc:title>Activation of the Farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential</dc:title>
<dcterms:dateAccepted>2015-11-12</dcterms:dateAccepted>
<rioxxterms:author first-named-author="true">Alasmael, N.</rioxxterms:author>
<rioxxterms:author first-named-author="false">Mohan, R.</rioxxterms:author>
<rioxxterms:author first-named-author="false">Meira, L. B.</rioxxterms:author>
<rioxxterms:author first-named-author="false">Swales, K. E.</rioxxterms:author>
<rioxxterms:author first-named-author="false">Plant, N. J.</rioxxterms:author>
<rioxxterms:publication_date>2016</rioxxterms:publication_date>
<rioxxterms:type>Article</rioxxterms:type>
<rioxxterms:version>NA</rioxxterms:version>
<rioxxterms:version_of_record>http://dx.doi.org/10.1016/j.canlet.2015.10.031</rioxxterms:version_of_record>
<rioxxterms:project rioxxterms:funder_name="Children’s Cancer Foundation" rioxxterms:funder_id="http://dx.doi.org/null">TEST-IDENTIFIER</rioxxterms:project>
</rioxx:rioxx>
</metadata>
</record>

Designed by Paul Walk, built with  Hugo v. 0.26
Copyright © Paul Walk. This website and blog are licensed under a Creative Commons Attribution-ShareAlike 3.0 Unported License